Children's brain tumour drug delivery consortium

Ruman Rahman, Richard Grundy, Emma Campbell, Henry Brem, Monica Pearl, Jordan Green, Miroslav Janoski, Kenneth Cohen, Piotr Walczak, Katherine Warren, Stephen Lowis, Alexander Mullen, Marie Boyd, Gareth Veal, Darren Hargrave, Dannis van Vuurden, Stephen Powell, David Walker

Research output: Contribution to journalConference Contribution

Abstract

INTRODUCTION: Whilst there is an urgent need to expedite the development of new or repurposed drugs for children’s cancer, the additional challenge in the developing brain is to ensure the drug is delivered to the tumour at therapeutic and non toxic concentrations for sufficient duration to achieve the biological effect. This is the necessary focus for personalised medicine agendas in children’s brain tumours as they account for over 20% of childhood cancer and differ significantly in their biological characteristics from their adult counterparts. METHODS: The authors took part in an international CNS drug delivery London workshop funded by the charity Children with Cancer UK (CwC) in February 2016 where different experimental techniques aimed at optimising CNS drug delivery in children’s brain tumours were presented and discussed. RESULTS: The workshop was reported (1) and promoted through e-cancer (2). We were encouraged to develop a proposal, to establish an international research consortium to raise awareness and promote collaboration in the field. This is now to be funded for two years by Children with Cancer. The Children’s Brain Tumour Drug Delivery Consortium will organise and host discussions between an international, multi-disciplinary network of clinicians and researchers within pharma and academia as well as a range of funders and stakeholders. This Consortium seeks to strengthen collaborative developments by working closely with the international children’s brain tumour community. CONCLUSION: We present this abstract to the SNO Pediatric conference to launch this initiative in North America and invite collaborators to promote this research priority for children across the world and to consider joining the consortium, which will be presented at the conference.
LanguageEnglish
Article numberTRTH-06
Pagesiv52
Number of pages1
JournalNeuro-Oncology
Volume19
Issue numbersuppl 4
DOIs
Publication statusPublished - 1 Jun 2017
Event4th Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research - New York City, United States
Duration: 15 Jun 201716 Jun 2017

Fingerprint

Brain Neoplasms
Pharmaceutical Preparations
Neoplasms
Drug Repositioning
Education
Charities
Precision Medicine
Poisons
North America
Research
Research Personnel
Pediatrics
Brain

Keywords

  • drug delivery
  • consortium
  • brain tumour
  • children
  • paediatric

Cite this

Rahman, R., Grundy, R., Campbell, E., Brem, H., Pearl, M., Green, J., ... Walker, D. (2017). Children's brain tumour drug delivery consortium. Neuro-Oncology, 19(suppl 4), iv52. [TRTH-06]. https://doi.org/10.1093/neuonc/nox083.218
Rahman, Ruman ; Grundy, Richard ; Campbell, Emma ; Brem, Henry ; Pearl, Monica ; Green, Jordan ; Janoski, Miroslav ; Cohen, Kenneth ; Walczak, Piotr ; Warren, Katherine ; Lowis, Stephen ; Mullen, Alexander ; Boyd, Marie ; Veal, Gareth ; Hargrave, Darren ; van Vuurden, Dannis ; Powell, Stephen ; Walker, David. / Children's brain tumour drug delivery consortium. In: Neuro-Oncology. 2017 ; Vol. 19, No. suppl 4. pp. iv52.
@article{947b9be8ee774192be8ab5f160a4e494,
title = "Children's brain tumour drug delivery consortium",
abstract = "INTRODUCTION: Whilst there is an urgent need to expedite the development of new or repurposed drugs for children’s cancer, the additional challenge in the developing brain is to ensure the drug is delivered to the tumour at therapeutic and non toxic concentrations for sufficient duration to achieve the biological effect. This is the necessary focus for personalised medicine agendas in children’s brain tumours as they account for over 20{\%} of childhood cancer and differ significantly in their biological characteristics from their adult counterparts. METHODS: The authors took part in an international CNS drug delivery London workshop funded by the charity Children with Cancer UK (CwC) in February 2016 where different experimental techniques aimed at optimising CNS drug delivery in children’s brain tumours were presented and discussed. RESULTS: The workshop was reported (1) and promoted through e-cancer (2). We were encouraged to develop a proposal, to establish an international research consortium to raise awareness and promote collaboration in the field. This is now to be funded for two years by Children with Cancer. The Children’s Brain Tumour Drug Delivery Consortium will organise and host discussions between an international, multi-disciplinary network of clinicians and researchers within pharma and academia as well as a range of funders and stakeholders. This Consortium seeks to strengthen collaborative developments by working closely with the international children’s brain tumour community. CONCLUSION: We present this abstract to the SNO Pediatric conference to launch this initiative in North America and invite collaborators to promote this research priority for children across the world and to consider joining the consortium, which will be presented at the conference.",
keywords = "drug delivery, consortium, brain tumour, children, paediatric",
author = "Ruman Rahman and Richard Grundy and Emma Campbell and Henry Brem and Monica Pearl and Jordan Green and Miroslav Janoski and Kenneth Cohen and Piotr Walczak and Katherine Warren and Stephen Lowis and Alexander Mullen and Marie Boyd and Gareth Veal and Darren Hargrave and {van Vuurden}, Dannis and Stephen Powell and David Walker",
year = "2017",
month = "6",
day = "1",
doi = "10.1093/neuonc/nox083.218",
language = "English",
volume = "19",
pages = "iv52",
journal = "Neuro-Oncology",
issn = "1522-8517",
number = "suppl 4",

}

Rahman, R, Grundy, R, Campbell, E, Brem, H, Pearl, M, Green, J, Janoski, M, Cohen, K, Walczak, P, Warren, K, Lowis, S, Mullen, A, Boyd, M, Veal, G, Hargrave, D, van Vuurden, D, Powell, S & Walker, D 2017, 'Children's brain tumour drug delivery consortium' Neuro-Oncology, vol. 19, no. suppl 4, TRTH-06, pp. iv52. https://doi.org/10.1093/neuonc/nox083.218

Children's brain tumour drug delivery consortium. / Rahman, Ruman; Grundy, Richard ; Campbell, Emma; Brem, Henry; Pearl, Monica; Green, Jordan; Janoski, Miroslav; Cohen, Kenneth; Walczak, Piotr; Warren, Katherine; Lowis, Stephen; Mullen, Alexander; Boyd, Marie; Veal, Gareth; Hargrave, Darren; van Vuurden, Dannis; Powell, Stephen; Walker, David.

In: Neuro-Oncology, Vol. 19, No. suppl 4, TRTH-06, 01.06.2017, p. iv52.

Research output: Contribution to journalConference Contribution

TY - JOUR

T1 - Children's brain tumour drug delivery consortium

AU - Rahman, Ruman

AU - Grundy, Richard

AU - Campbell, Emma

AU - Brem, Henry

AU - Pearl, Monica

AU - Green, Jordan

AU - Janoski, Miroslav

AU - Cohen, Kenneth

AU - Walczak, Piotr

AU - Warren, Katherine

AU - Lowis, Stephen

AU - Mullen, Alexander

AU - Boyd, Marie

AU - Veal, Gareth

AU - Hargrave, Darren

AU - van Vuurden, Dannis

AU - Powell, Stephen

AU - Walker, David

PY - 2017/6/1

Y1 - 2017/6/1

N2 - INTRODUCTION: Whilst there is an urgent need to expedite the development of new or repurposed drugs for children’s cancer, the additional challenge in the developing brain is to ensure the drug is delivered to the tumour at therapeutic and non toxic concentrations for sufficient duration to achieve the biological effect. This is the necessary focus for personalised medicine agendas in children’s brain tumours as they account for over 20% of childhood cancer and differ significantly in their biological characteristics from their adult counterparts. METHODS: The authors took part in an international CNS drug delivery London workshop funded by the charity Children with Cancer UK (CwC) in February 2016 where different experimental techniques aimed at optimising CNS drug delivery in children’s brain tumours were presented and discussed. RESULTS: The workshop was reported (1) and promoted through e-cancer (2). We were encouraged to develop a proposal, to establish an international research consortium to raise awareness and promote collaboration in the field. This is now to be funded for two years by Children with Cancer. The Children’s Brain Tumour Drug Delivery Consortium will organise and host discussions between an international, multi-disciplinary network of clinicians and researchers within pharma and academia as well as a range of funders and stakeholders. This Consortium seeks to strengthen collaborative developments by working closely with the international children’s brain tumour community. CONCLUSION: We present this abstract to the SNO Pediatric conference to launch this initiative in North America and invite collaborators to promote this research priority for children across the world and to consider joining the consortium, which will be presented at the conference.

AB - INTRODUCTION: Whilst there is an urgent need to expedite the development of new or repurposed drugs for children’s cancer, the additional challenge in the developing brain is to ensure the drug is delivered to the tumour at therapeutic and non toxic concentrations for sufficient duration to achieve the biological effect. This is the necessary focus for personalised medicine agendas in children’s brain tumours as they account for over 20% of childhood cancer and differ significantly in their biological characteristics from their adult counterparts. METHODS: The authors took part in an international CNS drug delivery London workshop funded by the charity Children with Cancer UK (CwC) in February 2016 where different experimental techniques aimed at optimising CNS drug delivery in children’s brain tumours were presented and discussed. RESULTS: The workshop was reported (1) and promoted through e-cancer (2). We were encouraged to develop a proposal, to establish an international research consortium to raise awareness and promote collaboration in the field. This is now to be funded for two years by Children with Cancer. The Children’s Brain Tumour Drug Delivery Consortium will organise and host discussions between an international, multi-disciplinary network of clinicians and researchers within pharma and academia as well as a range of funders and stakeholders. This Consortium seeks to strengthen collaborative developments by working closely with the international children’s brain tumour community. CONCLUSION: We present this abstract to the SNO Pediatric conference to launch this initiative in North America and invite collaborators to promote this research priority for children across the world and to consider joining the consortium, which will be presented at the conference.

KW - drug delivery

KW - consortium

KW - brain tumour

KW - children

KW - paediatric

UR - https://academic.oup.com/neuro-oncology/article/19/suppl_4/iv52/3859516

U2 - 10.1093/neuonc/nox083.218

DO - 10.1093/neuonc/nox083.218

M3 - Conference Contribution

VL - 19

SP - iv52

JO - Neuro-Oncology

T2 - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - suppl 4

M1 - TRTH-06

ER -

Rahman R, Grundy R, Campbell E, Brem H, Pearl M, Green J et al. Children's brain tumour drug delivery consortium. Neuro-Oncology. 2017 Jun 1;19(suppl 4):iv52. TRTH-06. https://doi.org/10.1093/neuonc/nox083.218